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Abstract
The discovery that microorganisms can be etiologic agents of disease has driven clinical, research 
and public health efforts to reduce exposure to bacteria. However, despite extensive campaigns to 
eradicate pathogens (via antibiotics, vaccinations, hygiene, sanitation, etc.), the incidence and/or 
severity of multiple immune-mediated diseases including, paradoxically, infectious disease have 
increased in recent decades. We now appreciate that most microbes in our environment are not 
pathogenic, and that many human-associated bacteria are symbiotic or beneficial. Notably, recent 
examples have emerged revealing that the microbiome augments immune system function. This 
review will focus on how commensal-derived signals enhance various aspects of the host response 
against pathogens. We suggest that modern lifestyle advances may be depleting specific microbes 
that enhance immunity against pathogens. Validation of the notion that absence of beneficial 
microbes is a risk factor for infectious disease may have broad implications for future medical 
practices.
Introduction
The discovery of antibiotics in the last century is one of the most significant achievements of 
modern medicine. Pathogens that once devastated entire civilizations, such as 
Mycobacterium tuberculosis, could finally be controlled, suggesting a triumph over 
infectious disease. However, the rampant rise of antibiotic resistance among pathogens, 
compounded by a drying pipeline of novel antibiotic development by pharmaceutical 
companies has rendered current therapeutic strategies ineffective. As such, we have entered 
the post-antibiotic era where pathogens once again reign with limited opposition and a minor 
scrape may pose the risk of a fatal infection [1,2]. To combat the renewed threat of 
pathogenic microorganisms, clinical approaches towards eradicating infectious disease must 
evolve.
The recent increase in the severity and incidence of Clostridium difficile-associated diarrhea 
(CDAD) is emblematic of medicine’s current failings as well as its possible future. The 
disruption of intestinal microbiota, most commonly by antibiotics, prompts infection by C. 
*To whom correspondence should be addressed: sarkis@caltech.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Curr Opin Microbiol. Author manuscript; available in PMC 2017 November 20.
Published in final edited form as:





















difficile resulting in disease that ranges from mild diarrhea to fulminant colitis [3]. Once 
fatal, the advent of antibiotics consigned it to a manageable infection. However, the spread 
of antibiotic-resistant, hypervirulent strains in recent years has created an epidemic that is 
exceedingly difficult to manage [4]. Currently, 20–25% of patients experience relapsing 
disease, further reflecting the reduced efficacy of antibiotic therapy [3]. Besieged by an 
unrelenting pathogen, clinicians began to supplement patients with the fecal contents of 
healthy donors in an attempt to reestablish the natural resistance afforded by the microbiota 
against C. difficile. Fecal transplantation embraces the hygiene hypothesis which argues 
microbial exposure, particularly that of commensal microbes, is beneficial to host health. 
This approach of administering microbes to combat disease is in shocking contrast to 
standard medical practices of the last century that, abiding by the principles of germ theory, 
indiscriminately targets microbes as a means of promoting individual health. Yet, achieving 
a 91% primary cure rate, the use of fecal transplantation insists upon a reassessment of our 
clinical strategy towards preventing and treating infectious disease [5].
The commensal microbiota is primarily comprised of indigenous bacteria that colonize the 
external interfaces of its host. Co-evolution has resulted in microbes with extensive and 
diverse impacts on multiple aspects of host biology including nutrient acquisition, immune 
development and neurological function [6–8]. Appropriately, conditions that disrupt the 
symbiotic host-microbial coexistence significantly alter predisposition to a wide spectrum of 
disorders. This review will focus on the contribution of commensal microbiota in promoting 
host resistance against infectious disease. Furthermore, we will discuss how efforts to 
support the integrity of the microbiota, as through bacteriotherapy or the supplementation 
with microbial products, may be an effective means of achieving protection against 
infection.
The intestinal microbiota promotes host resistance against mucosal 
infection
The development of enteric infection following antibiotic use has long been observed in both 
clinical practice and animal models of disease [3]. This observation suggests some 
mechanism by which the commensal microbiota protects against pathogen invasion and 
dissemination. The utilization of animal models to study the microbiota, including germ-free 
(GF) mice that lack microbial exposure, has revealed significant insight into the diverse and 
intricate contribution of the commensal microbes to host resistance against infectious 
disease.
Commensal microbes directly resist enteric pathogens
The commensal microbiota achieves resistance against opportunistic infection, in part, 
through niche competition. By competing for sites of colonization and nutrient uptake, 
commensal microbes are able to limit pathogen expansion at host epithelial surfaces [9]. GF 
mice are highly susceptible to enteric infection with Citrobacter rodentium, a murine 
pathogen used to model infection with enterohemorragic and enteropathogenic Escherichia 
coli [10]. Bacteriotherapy with isolated commensal microbes results in pathogen clearance, 
in part, due to the enhanced glycan acquisition capabilities of the transferred bacteria. These 
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findings reveal direct competition between commensal microbes and pathogens for nutrients 
as a means of limiting infection at sites of colonization.
Conversely, recent studies show that certain enteric pathogens are able to outcompete 
commensal microbes by actively triggering host inflammation which favors pathogen 
invasion and dissemination [11]. C. rodentium, Campylobacter jejuni, and Salmonella 
enterica serovar Typhimurium (STm) appear to induce inflammation as part of their 
infectious process, and increasing intestinal inflammation actually promotes disease [12,13]. 
Further, these reports surprisingly demonstrate that pathogen-induced inflammation 
adversely affects the microbiota, reducing the numbers of beneficial bacteria, which protect 
us from infections. Collectively, there is growing evidence for the notion that pathogens and 
symbiotic bacteria are engaged in an ‘evolutionary combat’, with the host serving as the 
battlefield.
Under conditions in which direct competition is insufficient to limit pathogen invasion, the 
commensal microbiota promotes resistance to infection by mediating protective host 
immune responses. Immune modulation by commensal microbes is indispensable in 
achieving host-microbial symbiotic coexistence and preventing inflammatory disease [7]. 
We now appreciate that this influence extends into supporting protection against infectious 
disease by promoting both barrier immunity as well as priming immune defenses against 
pathogen insult (Fig. 1).
Commensal microbes promote barrier immunity
Immune modulation by the microbiota occurs through commensal-derived signals such as 
microbial associated molecular patterns (MAMPs). Host recognition of MAMPs is achieved 
by pathogen recognition receptors (PRRs), such as Toll-like receptors (TLRs). At mucosal 
surfaces, these commensal-derived signals drive epithelial production of mucin, secretion of 
immunoglobulin A (IgA), and the expression of antimicrobial peptides (AMPs) that limit 
microbial contact to mucosal tissue [14–16]. One such example is commensal driven 
expression of RegIIIγ by intestinal epithelial cells (Fig. 2). RegIIIγ is a C-type lectin that 
possesses antimicrobial activity against Gram-positive microbes [17]. Expression of RegIIIγ 
requires TLR recognition of commensal MAMPs [18]. As such, disruption of the 
microbiota, as through antibiotic treatment, reduces production of RegIIIγ resulting in a 
breakdown of barrier immunity. As a consequence, antibiotic-treated mice are highly 
susceptible to opportunistic infection with enteric pathogens such as vancomycin-resistant 
enterococcus (VRE) [19]. Supplementation of antibiotic-treated mice with purified MAMPs 
is sufficient to prime RegIIIγ expression and achieve resistance against infection. VRE is a 
common cause of antibiotic-associated diarrhea and, similar to C. difficile, exceedingly 
difficult to treat. Herein is another example of how current treatment strategies predispose 
the host to secondary infections and how efforts to maintain the integrity of the microbiota 
or supplement it during antibiotic treatment may be effective in limiting susceptibly to 
opportunistic pathogens.
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Commensal microbes prime immune resistance to pathogen invasion
Under conditions in which barrier resistance fails, commensal microbes continue to limit 
pathogen dissemination by enhancing immune clearance mechanisms. One such mechanism 
by which the microbiota promotes host resistance is through priming interleukin-1 (IL-1) β 
expression. IL-1β is a proinflammatory cytokine that is expressed in an inactive form (pro 
IL-1β) that is subsequently cleaved by caspases following inflammasome activation [20]. 
Intestinal mononuclear phagocytes isolated from specific pathogen-free (SPF) mice express 
pro-IL-1β, which is deficient in cells isolated from GF mice [21]. Cleavage of pro-IL-1β 
into its active form occurs after challenge with pathogenic microorganisms, such as STm, 
but not following exposure to commensal microbes. This would suggest that commensal 
microbes promote pro-IL-1β expression among intestinal mononuclear cells, which is 
specifically activated following pathogen insult. Appropriately, commensal-driven pro-IL-1β 
expression enhances resistance to enteric infection with STm.
Additional mucosal immune responses are driven by the microbiota, including the 
differentiation of T-helper 17 (Th17) cells and IL-22 expression by intestinal NKp46+ cells 
[22,23]. While specific details for the role of both cell types in regulating commensal 
microbes remains to be revealed, both are critical in combating mucosal infection with C. 
rodentium. It thus appears that the microbiota drives certain immune responses, including 
the production of pro-IL-1β, with the primary purpose of promoting resistance to pathogenic 
infection.
Commensal microbes prevent pathogen invasion at colonization sites 
beyond the gut
While the majority of the studies assessing the contribution of the microbiota to host 
resistance to infection have focused on the gut, colonization by commensal microbes at other 
barrier sites also affords pathogen protection. Skin microbes prime local development of 
Th1, Th17 and IL-17+ gamma-delta T cells [24]. Cutaneous T cell differentiation by 
commensal microbes is achieved through MAMP-driven IL-1β signaling. This response is 
independent of the intestinal microbiota as oral antibiotic treatment, which reduced intestinal 
Th1 and Th17 cells, has no effect on the immune profile within the skin. Furthermore, 
colonization of GF mice with the prominent skin commensal Staphylococcus epidermidis is 
sufficient to rescue the defective immune response in GF mice. Priming of these immune 
responses by skin microbes is instrumental in promoting resistance against cutaneous 
infection with Leishmania major. Here we see a critical influence, afforded by commensal 
microbes, in localized host immune development and subsequent protection against 
infection.
Immune protection is also achieved by commensal microbes residing within the respiratory 
mucosa. Antibiotic-treated mice display reduced resistance to influenza infection [25]. 
Disease susceptibility is characterized by defective IL-1β production as well as reduced 
dendritic cell recruitment and T cell priming. As a consequence, antibiotic-treated animals 
display attenuated T cell and B cell responses following viral infection. Interestingly, 
depletion of the microbiota did not enhance susceptibility to infection with herpes simplex 
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virus type 2 or Legionella pneumophila indicating specificity for pathogens to which the 
microbiota promotes resistance. Intranasal inoculation with purified MAMPs, such as LPS, 
is sufficient to restore protective immunity to infection, as is, surprisingly, intrarectal MAMP 
administration. These findings suggest the imunoprotective properties of commensal 
microbes are not limited to the sites of colonization, but rather may extend to distal 
compartments and may even support host resistance against systemic infection.
Commensal microbes promote host resistance to systemic infection
While commensal microbes are physically restricted to external sites of colonization, their 
influence on host immune responses extends into systemic compartments. This concept was 
revealed with the finding that GF mice display a diminished splenic CD4+ T cell profile 
[26]. Monocolonization with a prominent intestinal commensal, Bacteroides fragilis, is 
sufficient to promote CD4+ T cell development within the spleen. The role of commensal 
microbes in driving systemic immune maturation suggests that disruption of the microbiota 
may compromise host immunity and increase susceptibility to systemic infection.
Deliberate depletion of the microbiota reduces resistance to systemic infection with 
Lymphocytic Choriomeningitis Virus (LCMV) [27]. Antibiotic-treated mice display 
increased viral burden as a consequence of attenuated anti-viral immune responses following 
infection. Macrophages isolated from antibiotic-treated mice are deficient in type I and II 
interferon (IFN) signaling, as well as in controlling viral replication ex vivo. This defect in 
innate immune resistance contributes to an impaired adaptive immune response, which 
includes deficient expansion and cytolytic activity of LCMV-specific CD8+ T cells as well 
as reduced serum titers of anti-LCMV IgG. Furthermore, the defect in anti-viral immunity 
among microbiota-depleted mice may also reflect altered transcriptional response following 
infection. Splenic mononuclear cells, isolated from GF mice, are deficient in expressing pro-
inflammatory cytokines when stimulated with purified MAMPs [28]. This defective 
response is associated with reduced transcription of various inflammatory response genes 
due to chromatin modification of the promoter region. These studies reveal a remarkable role 
for commensal microbes in programing host systemic defense responses during steady state 
conditions. Furthermore, as this influence is reversible, temporary depletion of the 
microbiota is sufficient to compromise systemic immune resistance to pathogen invasion.
In addition to priming anti-viral immune responses during steady state conditions, 
commensal microbes may also protect against systemic bacteremia. Neutrophils isolated 
from the bone marrow of antibiotic-treated or GF mice are attenuated in ex vivo killing of 
extracellular pathogens Staphylococcus aureus and Streptococcus pneumoniae [29]. This 
defect was reproduced in mice deficient in Nod1, a PRR which recognizes peptidoglycan 
derived meso-diaminopimelic acid (mesoDAP), but not in mice deficient in other PRRs. 
Molecules from intestinal microbes are found in the bone marrow neutrophil stores, 
indicating that direct stimulation by commensal MAMPs primes neutrophil activity. 
Appropriately, neutrophil antimicrobial activity among antibiotic-treated mice is rescued 
following stimulation with Nod1 ligand. While it remains to be shown that the absence or 
disruption of the microbiota actually reduces resistance to bacterial infection, these 
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collective findings suggest immune priming by commensal microbes is critical in promoting 
host resistance against systemic infections.
Defects in host-microbial symbiosis may predicate susceptibility to 
infection
Factors that determine an individual’s susceptibility to infectious disease remain largely 
unknown. Here we suggest that environmental and genetic influences that disrupt the 
microbiota or impede host sensing of commensal-derived signals may confer vulnerability to 
pathogen infection (Fig. 3). As discussed earlier, depletion of the microbiota through 
antibiotics is sufficient to compromise host immune function and increase the risk of 
opportunistic infection. Other environmental factors that disrupt the composition of the 
microbiota, including gastrointestinal infection or diet, may additionally serve as a risk 
factor for disease [12,30]. Susceptibility to infection may even persist long after exposure to 
the microbiota-disrupting agent. Tracking the intestinal commensal profile among patients 
taking oral antibiotics revealed recovery in the composition of the microbiota following 
cessation of therapy [31]. However, there is a delay of several weeks to months between the 
final antibiotic administration and recovery of the microbiota to the pre-treatment 
composition. This delay, in animal models, was associated with increased susceptibility to 
infection, reflecting persistent consequences of antibiotic therapy [32]. Alternatively, certain 
individuals display alterations for up to four years after antibiotic treatment, indicating a 
defect in microbiota resilience [33]. We speculate that such a defect, while asymptomatic, 
may compromise the protective contribution of the commensal microbiota to host immunity 
and weaken resistance against pathogenic insult.
Defects in host sensing of the beneficial influence of commensal microbes may also serve as 
a risk factor for disease. Nod2 is an intracellular PRR that recognizes muramyl dipeptide, a 
conserved structural moiety of bacterial peptidoglycan [34]. Nod2 signaling promotes 
expression of Paneth cell α-defensin, a class of antimicrobial peptides, that, similar to 
RegIIIγ, limits microbial contact with host tissue [35]. As a consequence of the diminished 
α-defensin production, Nod2-deficient mice display heightened susceptibility to 
gastroenteritis by Listeria monocytogenes. Furthermore, as homozygous mutations in this 
receptor are associated with increased incidence of Crohn’s disease, defects in host sensing 
of commensal signals may be a risk factor for inflammatory bowel disease (IBD) by 
reducing clearance of pathogenic bacteria [34]. Indeed, the finding that adhesive and 
invasive E. coli (AIEC) are tightly associated with the intestinal epithelium among patients 
with Crohn’s disease may support this notion [36].
Finally, the genetic selection of one’s microbiota composition may reflect individual 
susceptibility to infection. NIH Swiss (NIH) mice are naturally resistant to gastrointestinal 
infection with C. rodentium, compared to C3H/HeJ (HeJ) mice which develop lethal disease 
[37]. Resistance among NIH mice is associated with increased expression of IL-22 and 
RegIIIβ, relative to HeJ mice. As the microbiota drives the expression of both antimicrobial 
mediators, susceptibility to infection may be a function of gut bacterial community 
composition. To test this hypothesis, HeJ mice were depleted of microbiota through 
Khosravi and Mazmanian Page 6





















antibiotic treatment, and colonized with intestinal microbes from NIH mice. The bacterial 
community profile of transplanted mice was shown to resemble that of the NIH donor. 
Remarkably, transfer of commensal microbes from NIH to HeJ mice is sufficient to promote 
resistance to infection. Protection is associated with increased expression of IL-22 and 
RegIIIβ, and protection is lost following neutralization of IL-22. Reciprocally, 
transplantation of HeJ microbiota to NIH mice increased disease burden to C. rodentium. 
Finally, pups in the subsequent generation inherit the microbiomes transferred to their 
parents. Offspring remarkably display resistance patterns to C. rodentium infection relative 
to their microbiota composition, rather than their genetics. These data suggest that familial 
history of infectious disease may not only reflect the inheritance of susceptibility genes, but 
possibly the vertical transmission of a microbiota that is less protective against pathogen 
challenge.
Conclusion
The evidence summarized in this review suggests that disruption of the microbiota through 
environmental influences may compromise immune function, leading to increased 
susceptibility to infectious disease. In particular, we propose that antibiotic use may 
paradoxically promote bacterial and viral infections by depleting immune-promoting gut 
bacteria. For example, antibiotics are routinely administered in the hospital to patients 
admitted for various non-bacterial illnesses. Not only can this practice select for antibiotic-
resistant microbes (an extensively reported phenomenon), but may also lead to nosocomial 
infections by reducing the ability of the immune system to fight infections. Furthermore, 
antibiotic use over several generations may reduce gut bacteria diversity in entire 
populations, a notion proposed by the ‘disappearing microbiota’ hypothesis [38]. In cases 
where antimicrobial use is justified, we speculate that the administration of commensal-
derived products that promote immunity may represent a viable companion therapy to 
antibiotics. Given the rise of antibiotic resistance among pathogens and the potential loss of 
beneficial microbes in Western societies, efforts that support microbiome-mediated 
protection may be an effective approach to achieve resistance to infectious disease in the 
post-antibiotic era.
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• Commensal microbes are critical in promoting host resistance against 
infectious disease.
• Protection by the microbiota from infection can be achieved through direct 
competition with pathogenic microorganisms for space and/or nutrients.
• Priming of immune responses by the microbiota to combat pathogens 
represents a potentially novel approach to control infectious disease.
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Figure 1. The intestinal microbiota promotes three levels of protection against enteric infection
I, Saturation of colonization sites and competition for nutrients by the microbiota limit 
pathogen association with host tissue. II, Commensal microbes prime barrier immunity by 
driving expression of mucin, immunoglobulin A (IgA) and antimicrobial peptides (AMPs) 
that further prevents pathogen contact with host mucosa. III, Finally, the microbiota 
enhances immune responses to invading pathogens. This is achieve by promoting IL-22 
expression by T cells and NKp46+ cells, which increases epithelial resistance against 
infection, as well as priming secretion of IL-1B by intestinal monocytes (MΦ) and dendritic 
cells (DCs), which promotes recruitment of inflammatory cells into the site of infection. In 
conditions in which the microbiota is absent, such as following antibiotic treatment, there is 
reduced competition, barrier resistance and immune defense against pathogen invasion.
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Figure 2. The commensal microbiota primes barrier immunity
Direct stimulation of epithelial Toll-like receptors (TLRs) by commensal MAMPs primes 
expression of RegIIIγ (a). Production of RegIIIγ is essential to limit microbial contact with 
host mucosa. As such, defects in TLR function results in deficient RegIIIγ expression 
resulting in an increased association of commensal microbes with host tissue as well as a 
heighten risk of infection with enteric pathogens (b). Additionally, reduced TLR stimulation 
as a consequence of the depletion of the microbiota is sufficient to reduce RegIIIγ 
expression and render the host susceptible to infection.
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Figure 3. Disruption of host-microbial symbiosis as a risk factor for infectious disease
Exposure to pathogenic microorganisms is often insufficient to cause disease. Rather, 
susceptibility to infectious disease reflects deficient immune resistance to pathogen 
challenge. As such, exogenous and endogenous factors that directly compromise individual 
immune function (including genetic immune defects and chemotherapy) are significant risk 
factors for infection. We extend this model by proposing that the factors that disrupt the 
protective benefits of the commensal microbiota similarly compromise individual immune 
integrity and predispose to infectious disease.
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